secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenon Pharmaceuticals Inc. (XENE)
CIK:        0001582313
Form:       8-K
Filed at:   2022-06-21T23:59:59+00:00
Accession:  0001564590-22-023664
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenon announces positive FDA EOP2 meeting for XEN1101; Phase 3 to start H2 2022
-------------------------------------------------------------------------------

- FDA aligned on key Phase 3 elements; NDA submission planned after completion of X-TOLE2 trial plus existing Phase 2b data.
- XEN1101 Phase 3 program in focal onset seizures to begin second half 2022.
- Plans to initiate single Phase 3 trial (X-ACKT) for primary generalized tonic clonic seizures.
- Phase 2b X-TOLE met primary endpoint with p<0.001 across all doses; drug was well tolerated.
- Xenon expects differentiated profile based on Kv7 potassium channel mechanism and once-daily no-titration dosing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582313/000156459022023664/0001564590-22-023664-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582313/000156459022023664/xene-8k_20220621.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-023664

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer